Epigraph journal

Epigraph is the official newsletter of the International League Against Epilepsy’s membership. Complimentary to all members. No subscription required. Please send articles and news to Epigraph@ilae.org

Sign up to receive the Epigraph newsletter.

Latest from Epigraph

The ketogenic diet for super-refractory status epilepticus - Why and how?

Image of brain

Super refractory status epilepticus carries up to a 40% mortality rate and controlled clinical trials of any treatment are severely limited. The ketogenic diet is emerging as a potential treatment option for SRSE, and a recent article provides practical considerations on using the diet in these cases.

Podcast - The ketogenic diet for super-refractory status epilepticus

La dieta cetogénica para el estado epiléptico superrefractario: ¿por qué y cómo?

Person in coma

Music can soothe or energize, cheer us up or make us somber. Studies of a specific Mozart sonata suggest that music may also hold promise as an adjunct treatment option for epilepsy.

Podcast - Dieta cetogénica y estatus epiléptico súper refractario

Joint task force reassures clinicians, patients after US lamotrigine warning

Prescription bottle for Lamotrigine

Following a recent safety warning issued by the US Food and Drug Administration (FDA) on lamotrigine, an ad hoc joint task force of the ILAE and American Epilepsy Society (AES) published an advisory for health care professionals worldwide that discusses how to minimize cardiac-related safety risks in patients taking lamotrigine.

Comunicado del grupo de trabajo ad hoc de la ILAE y la Sociedad Americana de Epilepsia (AES) después de la advertencia de lamotrigina en Estados Unidos

Question mark made from pills
Tras la reciente advertencia de seguridad emitida por la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) sobre la lamotrigina, un grupo de trabajo ad hoc de la ILAE y la Sociedad Americana de Epilepsia (AES) ha elaborado un documento de revisión acerca de cómo minimizar los riesgos de seguridad en relación con patología cardíaca en pacientes en tratamiento con lamotrigina.